Moderna Inc. ($MRNA) Stock Forecast: Down 10.0% Today

What is Moderna Inc.?

Moderna (MRNA) is a biotechnology company known for its development of mRNA-based vaccines, including the COVID-19 vaccine. The overall market sentiment for biotech stocks has been mixed recently, with investors closely monitoring regulatory developments and clinical trial outcomes.

Why is Moderna Inc. going down?

MRNA stock is down 10.0% on Mar 6, 2026 15:26

• Moderna's bearish movement today could be attributed to profit-taking by investors after a period of strong gains or concerns about the company's future growth prospects.
• The news about PepGen's muscular dystrophy drug facing FDA hold may have negatively impacted Moderna, as it highlights the regulatory challenges and uncertainties in the biotech industry.
• Additionally, the wider loss and revenue miss by D-Wave Quantum could have spooked investors in the biotech sector, leading to a broader sell-off that affected Moderna's stock price.
• Overall, the combination of regulatory hurdles, financial performance of related companies, and profit-taking behavior likely contributed to Moderna's bearish movement today.

MRNA Price Chart

MRNA Technical Analysis

MRNA News

D-Wave Quantum Faces Wider Loss, Revenue Miss Sparks Stock Movement

D-Wave Quantum Inc. (NYSE: QBTS) saw its stock trading down by 7.75% despite a modest increase in revenue from $2.3M to $2.8M, as its Q4 net loss widened to $0.09 per share, exceeding analyst expectations of a $0.06 loss and missing revenue estimates of $3.6M. However, premarket trading showed an over 3% increase in shares, suggesting investor confidence in long-term gains or underlying strategic developments. The article suggests that investors might be looking beyond immediate financial setbacks, anticipating future technological breakthroughs, strategic alliances, or market acquisitions that could reshape the quantum computing industry.

https://www.timothysykes.com/news/d-wave-quantum-inc-qbts-news-2026_03_05/

PepGen muscular dystrophy drug gets ‘surprise’ hold from FDA

The FDA has placed a partial clinical hold on PepGen’s Phase 2 trial for its myotonic dystrophy type 1 (DM1) treatment, Freedom2, specifically concerning the inclusion of U.S. patients. The hold reportedly stems from preclinical mouse data submitted in mid-2024, which showed drops in blood pressure not observed in human trials. Despite this setback, PepGen continues its Phase 2 work in other countries, and analysts suggest the issue may be resolvable as it appears to be a mouse-specific finding.

https://www.biopharmadive.com/news/pepgen-fda-hold-myotonic-dystrophy-drug-trial/813883/

Con Edison Is Up 13% in 2026: Here’s Why Analysts Still See 47% Upside

Con Edison (ED) is up 13% in 2026, driven by a $37.7 billion capital investment plan through 2030 and a recently approved three-year rate case. While the stock has increased, TIKR's valuation model suggests a 46.9% total return by 2030, indicating the market may be underpricing the utility's earnings durability and growth story. Analysts maintain a mean price target of $109.6, but some see a bull case of $130 (and a TIKR model target of $165.23) given the company's dividend history and regulatory protections.

https://www.tikr.com/blog/con-edison-is-up-13-in-2026-heres-why-analysts-still-see-47-upside

The Escalator: Seres Therapeutics, Bavarian Nordic, Moderna and more

This article details recent personnel changes and significant news across the pharmaceutical, biotech, and medical marketing industries. It highlights new hires, executive promotions, board appointments, and notable departures, including CEOs from Sarepta Therapeutics and Bavarian Nordic. Additionally, it covers miscellaneous industry news, such as comments from Pfizer's CEO and leadership changes within government health advisory committees.

https://www.mmm-online.com/news/the-escalator-seres-therapeutics-bavarian-nordic-moderna-and-more/

Cancer therapy firm Immatics funds 2028 runway despite $231M 2025 loss

Immatics (NASDAQ: IMTX) reported full-year 2025 financial results, announcing $551.4 million in cash and financial assets as of December 31, 2025, which extends its cash runway into 2028. The company reported a net loss of $230.8 million for 2025 and saw total revenue decline to $56.8 million due to a one-time non-cash revenue recognition in 2024. Immatics is advancing its PRAME franchise, including its lead asset anzu-cel, with key clinical milestones expected in 2026 and a BLA submission planned for the first half of 2027.

https://www.stocktitan.net/news/IMTX/immatics-announces-full-year-2025-financial-results-and-business-eqr4mk1jqwg3.html

Trending Today

Fortune Brands Innovations Inc. ($FBIN) Stock Forecast: Down 5.2% Today

The Cooper Companies Inc. ($COO) Stock Forecast: Down 5.1% Today

Carnival Corporation ($CCL) Stock Forecast: Down 5.1% Today

Bruker Corporation ($BRKR) Stock Forecast: Down 5.1% Today

V.F. Corporation ($VFC) Stock Forecast: Down 5.0% Today

Revvity ($RVTY) Stock Forecast: Down 5.1% Today

SolarEdge Technologies, Inc. ($SEDG) Stock Forecast: Down 5.5% Today

Intel Corporation ($INTC) Stock Forecast: Down 5.0% Today

IPG Photonics Corporation ($IPGP) Stock Forecast: Down 5.7% Today

ARM Holdings plc ($ARM) Stock Forecast: Down 5.5% Today

Moderna Inc. Price History

02.02.2026 - MRNA Stock was up 5.2%

• Moderna's stock saw an upward trajectory after receiving endorsement from the CHMP for its mCombriax COVID-19 and influenza combination vaccine. This favorable development, supported by promising Phase III study results, signifies a significant stride towards approval in the EU and potentially beyond.
• A price target increase by Piper Sandler for Moderna mirrors confidence in the company's vaccine portfolio, which includes upcoming milestones like the PDUFA date for the flu vaccine and Phase III melanoma data. Investors are reacting positively to the growth opportunities highlighted by Piper Sandler, despite ongoing safety concerns linked to mRNA technology.
• The positive trend in Moderna's stock stands in contrast to the challenges being tackled by other biotech firms such as Annovis Bio, CRISPR Therapeutics, and Alnylam Pharmaceuticals, as each navigates its distinct developments and regulatory environments.
• In summary, Moderna's bullish movement today is a result of favorable regulatory endorsements, advancements in its pipeline, and market enthusiasm surrounding its vaccine technologies, despite lingering safety considerations.

02.02.2026 - MRNA Stock was up 5.6%

• Moderna's stock rose after receiving a favorable opinion from the European Medicines Agency's drug review committee for its dual Covid-flu vaccine. This places Moderna at the forefront of the global competition for a combined vaccine.
• Concerns expressed by Pfizer's CEO regarding FDA leadership and internal disagreements on vaccine strategies may have indirectly benefitted Moderna, highlighting potential regulatory advantages for the company.
• Analysts have a positive view on Moderna's stock, increasing price targets and emphasizing its robust vaccine pipeline, contributing to investor confidence and the stock's upward movement.
• Moderna's strategic shift towards cancer and rare disease pipelines, in addition to potential regulatory approvals across various regions, showcases the company's diversification beyond Covid-19 vaccines, making it an appealing option for investors.

04.02.2026 - MRNA Stock was up 7.6%

• Following the announcement of a $950 million settlement to resolve patent infringement claims with Arbutus Biopharma Corp and Genevant Sciences GmbH, Moderna's stock saw a notable bullish trend.
• This settlement eliminated a significant financial risk for Moderna, increasing investor confidence in the company's future.
• Despite the substantial settlement, investors interpreted this news positively for Moderna, resulting in the bullish market movement.
• The information about the settlement overshadowed insider sales at Axsome Therapeutics and routine equity compensation activities at Molson Coors Beverage Co, underscoring the impact of legal resolutions on market sentiment.

04.02.2026 - MRNA Stock was up 13.4%

• Moderna's stock saw a notable rise following the resolution of patent disputes with Arbutus and Roivant, resulting in a settlement of up to $2.25 billion. This development brought clarity to Moderna's mRNA pipeline and eliminated a substantial financial risk.
• The settlement news generated optimism among investors regarding Moderna's forthcoming product innovations and potential revenue sources.
• Investor sentiment was positively influenced by the resolution of the legal issues, underscoring the importance of Moderna's capacity for innovation and product launches in sustaining long-term growth and success.

05.02.2026 - MRNA Stock was down 5.5%

• Moderna experienced a bearish movement possibly due to the settlement it reached with Roivant Sciences and Arbutus Biopharma, which involved significant payouts, impacting its financials negatively.
• The positive news of being a top leader among stocks on Wednesday might have been overshadowed by the impact of the settlements on Moderna's finances.
• The increase in headcount by some Massachusetts biotech companies, including Moderna, in 2025, could indicate potential operational expansions that might have been affected by the recent legal settlements.

23.01.2026 - MRNA Stock was up 6.0%

• Moderna experienced a strong bullish movement today due to multiple factors:
• Gilead Sciences' acquisition of Arcellx, focusing on CAR T-cell therapy, brought positive attention to the biotech sector and potentially increased investor confidence in similar companies like Moderna.
• The FDA's decision to review Moderna's mRNA flu vaccine and the initiation of the review for its investigational seasonal influenza vaccine submission (mRNA-1010) signaled progress and potential future revenue streams for the company.
• Despite facing legal challenges related to patent infringement and mixed financial results, including declining revenue, the positive developments with FDA reviews and vaccine submissions outweighed the concerns for investors.
• Telemark Asset Management LLC's significant acquisition of Moderna shares also indicated confidence in the company's future prospects, contributing to the bullish movement.

24.01.2026 - MRNA Stock was down 6.5%

• The bearish movement in MRNA's stock today is linked to concerns over potential FDA actions on mRNA vaccines, causing uncertainty and regulatory hurdles for the company's future vaccine developments.
• The negative revenue outlook and financial challenges may have led to investor caution and selling pressure on the stock.
• Despite recent positive updates, such as regulatory approvals and strategic agreements, the market sentiment appears to have been influenced more by broader challenges and uncertainties facing Moderna, resulting in the bearish movement in the stock today.

05.02.2026 - MRNA Stock was up 7.7%

• Moderna's recent positive developments include a substantial $2.25 billion settlement with Roivant Sciences, resolving patent disputes on lipid nanoparticle technology in COVID-19 vaccines. This settlement not only removes a legal overhang but also shows the company's ability to protect its intellectual property rights effectively.
• Another significant development is Moderna's $950 million settlement with Arbutus Biopharma, providing clarity and resolution on a patent infringement lawsuit related to its Covid-19 vaccine, Spikevax.
• The company's decision to add workers in 2025 amidst industry-wide layoffs suggests strategic growth plans and commitment to expanding its workforce to support research and development efforts, potentially boosting investor confidence in the stock.
• These settlements, coupled with workforce expansion and positive industry developments, may have contributed to investor optimism in Moderna, driving its strong bullish movement in the market.

25.01.2026 - MRNA Stock was up 5.6%

• Despite concerns about Moderna's financial standing, the stock has shown a notable recovery in its share price, signaling growing investor confidence.
• Positive outlook in the options market for Moderna, evident by the majority of trades predicting favorable outcomes, aligns with the current upward trend of the stock.
• Moderna's recent announcement about the FDA's review of its new mRNA flu vaccine, following dispute resolutions, likely contributed to the optimistic market sentiment and stock price surge.
• Protalix Biotherapeutics' strong performance, reaching a new 52-week high, reflects the overall robustness in the pharmaceuticals and biotechnology sector, potentially bolstering investor trust in companies like Moderna.

06.02.2026 - MRNA Stock was down 10.0%

• Moderna's bearish movement today could be attributed to profit-taking by investors after a period of strong gains or concerns about the company's future growth prospects.
• The news about PepGen's muscular dystrophy drug facing FDA hold may have negatively impacted Moderna, as it highlights the regulatory challenges and uncertainties in the biotech industry.
• Additionally, the wider loss and revenue miss by D-Wave Quantum could have spooked investors in the biotech sector, leading to a broader sell-off that affected Moderna's stock price.
• Overall, the combination of regulatory hurdles, financial performance of related companies, and profit-taking behavior likely contributed to Moderna's bearish movement today.

03.02.2026 - MRNA Stock was down 6.2%

• The decline in Moderna's stock today is possibly due to investors taking profits following a period of successful performance.
• Merck's notable revenue growth fueled by Keytruda, a competitor PD-1 inhibitor, might have sparked concerns about potential competition for Moderna in the immuno-oncology sector.
• The proposed stock offering by MAIA Biotechnology to finance trials could have affected Moderna's stock price, as investors may be wary of potential dilution in the biotech industry.
• Despite optimistic outlooks from analysts and advancements in its pipeline, general market sentiment regarding regulatory approvals and market acceptance of Moderna's mRNA-based vaccines may be influencing the stock's movements.

03.02.2026 - MRNA Stock was down 6.3%

• Analysts are bullish on Moderna, maintaining Buy ratings and positive price targets, indicating long-term growth potential.
• The transition to a more diversified business model, including RSV and flu vaccines, has garnered investor interest, but concerns remain regarding regulatory approvals and market adoption.
• The decline in Moderna's stock price could be attributed to the negative market reaction to MAIA Biotechnology's stock sale announcement, raising concerns about potential dilution for existing shareholders.
• Despite positive news of Moderna's dual Covid-flu vaccine nearing EMA approval, regulatory hurdles in the US for other vaccines and shifting focus to different pipelines may have contributed to the bearish market movement.